Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 17,702 shares of Oxford BioMedica stock in a transaction dated Wednesday, May 23rd. The shares were bought at an average price of GBX 15 ($0.20) per share, for a total transaction of £2,655.30 ($3,535.22).
Lorenzo Tallarigo also recently made the following trade(s):
- On Monday, April 23rd, Lorenzo Tallarigo acquired 22,055 shares of Oxford BioMedica stock. The stock was bought at an average price of GBX 12 ($0.16) per share, for a total transaction of £2,646.60 ($3,523.63).
- On Thursday, March 22nd, Lorenzo Tallarigo acquired 22,066 shares of Oxford BioMedica stock. The stock was bought at an average price of GBX 12 ($0.16) per share, for a total transaction of £2,647.92 ($3,525.39).
- On Friday, February 23rd, Lorenzo Tallarigo acquired 22,121 shares of Oxford BioMedica stock. The stock was bought at an average price of GBX 12 ($0.16) per share, for a total transaction of £2,654.52 ($3,534.18).
LON:OXB traded down GBX 13.20 ($0.18) on Thursday, reaching GBX 990 ($13.18). 278,461 shares of the company’s stock were exchanged, compared to its average volume of 6,890,000. Oxford BioMedica plc has a 52-week low of GBX 4.44 ($0.06) and a 52-week high of GBX 13.19 ($0.18).
Several brokerages recently issued reports on OXB. Peel Hunt restated a “buy” rating and issued a GBX 16 ($0.21) price objective on shares of Oxford BioMedica in a report on Tuesday, May 1st. Jefferies Financial Group lowered shares of Oxford BioMedica to a “hold” rating in a report on Wednesday.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.